Pembrolizumab in Combination With Gemcitabine in People With Advanced

See also
Status	Clinical Trial	Phase
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Not yet recruiting	`NCT02881749` - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides	Phase 2
Completed	`NCT00051012` - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients	Phase 4
Terminated	`NCT03789864` - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides	N/A
Completed	`NCT01590732` - Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma	Phase 1
Recruiting	`NCT02848274` - ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting	`NCT00177268` - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting	`NCT05357794` - Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides	Phase 2
Completed	`NCT04955340` - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat	Phase 1
Completed	`NCT02883517` - Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Active, not recruiting	`NCT02953301` - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)	Phase 2
Completed	`NCT00254332` - Effect of Denileukin Diftitox on Immune System in CTCL Patients	N/A
Completed	`NCT02296164` - Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Recruiting	`NCT05680558` - Photopheresis in Early-stage Mycosis Fungoides	Phase 2
Completed	`NCT00038376` - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies	Phase 2
Completed	`NCT00168064` - Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides	Phase 2
Recruiting	`NCT05879458` - Ritlecitinib in CTCL	Phase 2
Recruiting	`NCT05414500` - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides	Phase 1
Recruiting	`NCT05904522` - Histopathological Changes in Mycosis Fungoides	N/A
Recruiting	`NCT04256018` - Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome	Phase 2

NCT number	NCT04960618
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Alison Moskowitz, MD
Phone	646-608-3726
Email	moskowia@mskcc.org
Status	Recruiting
Phase	Phase 2
Start date	October 1, 2021
Completion date	July 2025

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms